PRESS RELEASE: Neurocrine Biosciences Enters into $108 Million Sale and Leaseback Agreement for its Real Estate Assets

Neurocrine Biosciences Enters into $108 Million Sale and Leaseback Agreement for its Real Estate Assets

SAN DIEGO, Nov. 1 -- Neurocrine Biosciences, Inc. announced today that the Company has entered into a sale and leaseback agreement with Veralliance Properties for its real estate assets, with an expected closing date before year-end 2007. Total consideration to be received by Neurocrine for the properties is $108 million. Concurrently with the closing of the transaction, Neurocrine will lease back its corporate headquarters under a lease with a 10 year term. Neurocrine has certain options to repurchase all of the properties included in the transaction during the term of the lease. Under the terms of the asset purchase agreement, Neurocrine anticipates that it will receive cash of approximately $60 million net of fees, expenses and existing indebtedness.

"Owning the properties that Neurocrine occupies has been a highly profitable strategy for the Company and our shareholders, allowing us to benefit from the appreciation in the San Diego commercial real estate market," said Timothy P. Coughlin, Vice President and Chief Financial Officer of Neurocrine Biosciences. "Improving our strong financial position at this time in a non-dilutive manner provides us with the financial flexibility to advance our clinical and research programs and build equity in our pipeline."

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurological and endocrine diseases and disorders. The product candidates address some of the largest pharmaceutical markets in the world including insomnia, anxiety, depression, endometriosis, irritable bowel syndrome, pain, and diabetes. Neurocrine Biosciences, Inc. news releases are available through the Company's website via the Internet at http://www.neurocrine.com

In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general. Other risks are described in the Company's report on Form 10-K for the year ended December 31, 2006 and Form 10-Q for the quarter ended June 30, 2007. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.